- NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells
Tao Tao et al, 2017, IJMS CrossRef - Isoquercitrin inhibits bladder cancer progression in vivo and in vitro by regulating the PI3K/Akt and PKC signaling pathways
FENG CHEN et al, 2016 CrossRef - Design, synthesis and pharmaco-toxicological assessment of 5-mercapto-1,2,4-triazole derivatives with antibacterial and antiproliferative activity
Marius Mioc et al, 2017 CrossRef - MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathway
Liang Shen et al, 2015, Tumor Biol. CrossRef - Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer.
Anuja Sathe et al, 2018, Methods Mol Biol CrossRef - GSK3β-dependent cyclin D1 and cyclin E1 degradation is indispensable for NVP-BEZ235 induced G0/G1 arrest in neuroblastoma cells
Shan-Ling Liu et al, 2017, Cell Cycle CrossRef - Prospects for precision therapy of bladder urothelial carcinoma
Nuno Vau et al, 2017, Expert Review of Precision Medicine and Drug Development CrossRef - Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway
Jia-Teng Zhong et al, 2017, Tumour Biol. CrossRef - Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38
Katharina Gohr et al, 2017, BMC Cancer CrossRef - Muscle-invasive urothelial bladder cancer: an update on systemic therapy
Hayley Knollman et al, 2015, Therapeutic Advances in Urology CrossRef - Colorectal cancer lung metastasis treatment with polymer–drug nanoparticles
Piotr Rychahou et al, 2018, Journal of Controlled Release CrossRef - Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
Yang Liu et al, 2018, Sci Rep CrossRef - NVP-BEZ235, a dual PI3K-mTOR inhibitor, suppresses the growth of FaDu hypopharyngeal squamous cell carcinoma and has a synergistic effect with Cisplatin
Cheng-Ming Hsu et al, 2018, Cell Death Discovery CrossRef - Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation
Feng Ni et al, 2018, Cancer Chemother Pharmacol CrossRef - NVP-BEZ235 Attenuated Cell Proliferation and Migration in the Squamous Cell Carcinoma of Oral Cavities and p70S6K Inhibition Mimics its Effect
Cheng-Ming Hsu et al, 2018, IJMS CrossRef - Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells
J.Y. Cao et al, 2017, Braz J Med Biol Res CrossRef - Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity
David E. Durrant et al, 2015, Mol Pharmacol CrossRef - Emerging therapeutic targets in bladder cancer
Benedito A. Carneiro et al, 2015, Cancer Treatment Reviews CrossRef - Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models
Stefanie Schrauwen et al, 2015, Gynecologic Oncology CrossRef - Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma
Yun-Rong Zhu et al, 2015, Cancer Biology & Therapy CrossRef - Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN)
S S Islam et al, 2016, Targ Oncol CrossRef - Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling
Banu Iskender et al, 2016, Tumor Biol. CrossRef - miR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cells
Li-Ping Zeng et al, 2016, J. Cell. Mol. Med. CrossRef - Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma
Emmanuel Seront et al, 2016, BJU Int CrossRef - Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU)
Jorge García et al, 2016, Curr Oncol Rep CrossRef - Effect of exogenous TGF-β1 on the cadmium-induced nephrotoxicity by inhibiting apoptosis of proximal tubular cells through PI3K-AKT-mTOR signaling pathway
Minyi Huang et al, 2017, Chemico-Biological Interactions CrossRef - Blockage of Autophagy Rescues the Dual PI3K/mTOR Inhibitor BEZ235-induced Growth Inhibition of Colorectal Cancer Cells
Iljoong Oh et al, 2016, Dev Reprod CrossRef - Emerging Roles of Cancer Stem Cells in Bladder Cancer Progression, Tumorigenesis, and Resistance to Chemotherapy: A Potential Therapeutic Target for Bladder Cancer
Amira Abugomaa et al, 2020, Cells CrossRef - Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma
Jordan F Hastings et al, 2020 CrossRef - Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells
Hyung Joon Kim et al, 2020, Yonsei Med J CrossRef - Bioinformatics analysis of microRNA expression between patients with and without latent tuberculosis infections
Yang Lu et al, 2019, Exp Ther Med CrossRef - An overview on precision therapy in bladder cancer
Ahmed Sayed et al, 2020, Expert Review of Precision Medicine and Drug Development CrossRef - Combined CDKN1A/TP53 Mutation in Bladder Cancer Is a Therapeutic Target
Yang Liu et al, 2015, Mol Cancer Ther CrossRef - Novel Combination Therapies for the Treatment of Bladder Cancer.
Mei Peng et al, 2020, Front Oncol CrossRef - Antitumor Activity of Nanoparticles Loaded with PHT-427, a Novel AKT/PDK1 Inhibitor, for the Treatment of Head and Neck Squamous Cell Carcinoma
Joaquín Yanes-Díaz et al, 2021, Pharmaceutics CrossRef - Quinoline-based Compounds with Potential Activity against Drugresistant Cancers
Huan-Ting Li et al, 2021, CTMC CrossRef - Autophagy Modulation and Cancer Combination Therapy: A Smart Approach in Cancer Therapy
Ali Salimi Jeda et al, 2022, Cancer Treatment and Research Communications CrossRef - The Anti-Proliferative Effect of PI3K/mTOR and ERK Inhibition in Monolayer and Three-Dimensional Ovarian Cancer Cell Models.
Elizabeth Dunn et al, 2022, Cancers (Basel) CrossRef - Recent Advances in the Development of Noble Metal NPs for Cancer Therapy
Rui Zhao et al, 2022, Bioinorganic Chemistry and Applications CrossRef - Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy
Jianya Huan et al, 2022, Cancers CrossRef - Ce6- and Bez235-Based Nanomedicine for Chemo-/Photodynamic Combination Therapy of Tumors
Fu-An Deng et al, 2022, ACS Appl. Nano Mater. CrossRef - A Short Overview on Therapeutic Biomarkers for Muscle Invasive Bladder Carcinoma
, 2023, EMJ Urol CrossRef - Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages
Weimin Hu et al, 2023, Heliyon CrossRef - Mechanism of anticancer effect of ETP-45658, a PI3K/AKT/mTOR pathway inhibitor on HT-29 Cells
Fatih Yulak et al, 2023, Med Oncol CrossRef - Systemic treatment options in bladder cancer
Rahul Ravind et al, 2018, Cancer Res Stat Treat CrossRef - Casticin-Induced Inhibition of Cell Growth and Survival Are Mediated through the Dual Modulation of Akt/mTOR Signaling Cascade.
Jong Hyun Lee et al, 2019, Cancers (Basel) CrossRef - Landscape of targeted therapies for advanced urothelial carcinoma
Shihao Shang et al, 2024 CrossRef - Prognostic analysis of anoikis-related genes in bladder cancer: An observational study
Fu Huang et al, 2024 CrossRef - null
Ursu Ramona Gabriela et al, 2024 CrossRef - Redefining bladder cancer treatment: innovations in overcoming drug resistance and immune evasion
Peng Huang et al, 2025, Front. Immunol. CrossRef